DOCSLIB.ORG

Firms in the United States Commercializing Biotechnology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Firms in the United States Commercializing Biotechnology Appendix D Firms in the United States Commercializing Biotechnology Table 4 in Chapter 4: Firms Commerializing Fermentation Industries, Inc.) are missing from the list, Biotechno]ogy listed firms in the United States com- because sufficient information to confirm their activ- mercializing biotechnology and their product markets. ities could not be obtained. Like the biotechnology re- Their names and addresses are provided below. In search of established companies, the existence of new order for a company to be listed in table 4, the ex- biotechnology firms (NBFs) is often difficult to confirm. istence of the company and the fact that the company More than 10 new companies, not included here, are is pursuing the development of biotechnology as de- thought by OTA to be operating but with very little fined by OTA had to be confirmed by at least two public visibility. Some established companies and NBFs sources (e.g., company directories, individuals, trade regard the application of their biotechnology research journals). The existence and commercial application to be proprietary, and others will not even publicly areas of many of the companies listed also were con- confirm whether or not they are involved in biotech- firmed through the survey of firms’ personnel needs nology. Approximately 10 companies are not listed for conducted by the National Academy of Sciences and this reason. Various other companies are not listed, OTA. * because their existence and involvement in biotech- The number of companies listed in table 4 is a very nology were not confirmed by at least two sources. conservative estimate of the number of companies Most support firms are not included in the table, be- commercializing biotechnology in the United States. cause they are not applying biotechnology to the pro- More than five established companies thought to be duction of their products. Those support companies applying novel bioprocessing technology (e.g., G. B. that, in addition to supplying support products (e.g., restriction enzymes and oligonucleotides), are apply- ing biotechnology to the development and production “All but 33 of the firms listed were sent the OTA/NAS survey question- naire, which is repmdumd in Appendix E: OTAfNAS Survey of Personnel of such products as vaccines and monoclinal anti- Needs of R“rms in the United States. bodies are included. Abbott Laboratories Allied Chemical Corp. Angenics 14th St. & Sheridan Rd. Columbia Rd. & Park Ave. 100 Inman St. North Chicago, Ill. 60064 P.o. Box 4oom Cambridge, Mass. 02139 Actagen Morristown, N.J. 07960 Animal Vaccine Research Corp. Rm. 802 Alpha Therapeutic Corp. 3333 Torrey Pines Ct., Suite 120 99 Park Ave. 5555 Valley Blvd. La Jolla, Catif. 92037 New York, N.Y. 10016 Los Angeles, Calif. 90032 Antibcxiies, Inc. Advanced Biotechnology Associates, Inc. Ambico, Inc. P.O. BOX 442 177 Post St., Suite 700 P.O. Box M, Route 2 Davis, Calif. 95617 San Franciso, Calif. 94108 Dallas Center, Iowa 50063 Applied DNA Systems, Inc. Advanced Genetic Sciences, Inc. American Cyanamid Co, 4415 Fifth Ave. 42 Maher Ave. One Cyanamid Plaza Pittsburgh, Pa. 15213 Greenwich, Corm, 06830 Wayne, N.J. 07470 Applied Genetics, Inc. Advanced Genetics Research Institute American Diagnostics Corp. 5 Jules Lane 2220 Livingston St. 1600 Monrovia Ave. New Brunswick, N.J. 08901 Berkeley, Calif. 94606 Newport Beach, Calif. 92663 ARCO Plant Cell Research Institute Advanced Mineral Technologies, Inc. American Quahx 6560 Trinity Ct. P.o. Box 1339 14620 Firestone Blvd. Dublin, calif, 94568 Socorro, N. Mex. 87801 La Mirada, Calif. 90638 Atlantic Antibodies Agrigenetics Corp. Amgen 10 Nonesuch Rd. 3375 Mitchell Lane 1892 Oak Terrace Lane P.O. BOX 60 Boulder, Colo. 80301 Newbury Park, Calif. 91320 Scarborough, Maine 04074 542 App. D—Firms in the United States Commercializing Biotechnology ● 543 Axonics BTC Diagnostics, Inc. Collaborative Genetics, nc. 1500 Salado Dr., Suite 202 61 Moulton St. 128 Spring St. Mountain View, Calif. 94043 Cambridge, Mass. 02138 Lexington, Mass. 01273 Baxter-Travenol Laboratories, Inc. Calgene Collagen, Inc. One Baxter Parkway 1910 Fifth St. 2455 Faber P1. Deerfield, Ill. 60015 Davis, Calif. 95616 Palo Alto, Calif. 94303 Becton Dickinson & Cb. California Biotechnology, Inc. Cooper Diagnostics, Inc. Corporate Research Center 2450 Bayshore Frontage Rd. 1230 Wilson Dr. P.O. BOX 12016 Mountain View, Calif. 94303 West Chester, Pa. 19380 Research Triangle Park, N.C. 27709 Cambridge Bioscience Corp. Cooper-Lipotech, Inc. Bethesda Research Laboratories, Inc 495 Old Connecticut Path 1030 Curtis St. P.o. Box 577 Framingham, Mass. 01701 Merdo Park, Calif. 94025 Grovemont Circle Campbell Institute for Research and Corning Glass Works Gaithersburg, Md. 20760 Technology Corning Biotechnology Department Biocell Technology Corp. Campbell Soup Co. Baron Steuben Plaza 22o East 23rd St. Campbell Rd. Corning, N.Y. 14830 New York, N.Y. 10010 Camden, N.J. 08101 Crop Genetics International Biochem Technology, Inc. Celanese Research Co. 7170 Standard Dr. 66 Great Valley Parkway 86 Morris Ave. Dorsay, Md. 21076 Great Valley Corporate Center Summit, N.J. 07901 Cutter Laboratories, Inc. Malvern, Pa. 19355 Cellorgan International, Inc. 2200 Powell St. Bio-con, Inc. 300 Park Ave. P.O. BOX 8817 3601 Gibson St. New York, N.Y. 10010 Emeryville, Calif. 94662 P.O. BOX 5277 Celtek, Inc. Cytogen Corp. Bakersfield, Calif. 93388 102 West Eufala 201 College Rd., East Biogen, Inc. Norman, C)kla. 73069 Princeton Forrestal Center 241 Binney St. Centaur Genetics Corp. Princeton, N.J. 08540 Cambridge, Mass. 02142 120 South LaSalle St., Suite 825 Cytox Corp. BioGenex Laboratories Chicago, 111.60603 954 Marcon Blvd. 6529 Sierra Lane Centocor Allentown, Pa. 18103 Dublin, Calif. 94566 3508 Market St. Dairyland Foods Corp. Biological Energy Corp. Philadelphia, Pa. 19104 620 Progress Ave. P.o. Box 766 Cetus Corp. Waukesha, Wis. 53187 2650 Eisenhower Ave. 600 Bancroft Way Damon Biotech, Inc. Valley Forge, Pa. 19482 Berkeley, Calif. 94710 115 Fourth Ave. Bio Response, Inc. Cetus Immune Corp. Needham Heights, Mass. 02194 55o Ridgefield Rd. 34OO West Bayshore Rd. Dart & Kraft, Inc. Wilton, Corm. 06987 Palo Alto, Calif. 94303 2211 Sanders Rd. Biotech Research Laboratories, Inc. Cetus Madison Corp. Northbrook, Ill. 60062 1600 East Gude Dr. 2208 Parkview Rd. Davy McKee Corp. Rockville, Md. 20850 Middleton, Wis. 53562 10 South Riverside Plaza Biotechnica International, Inc. Chiron Corp. Chicago, 111.60606 85 Bolton St. 4560 Horton St., Suite 0214 DeKalb Pfizer Genetics Cambridge, Mass. 02140 Emeryville, Calif. 94608 Sycamore Rd. Bio-Technology General Corp. CibaGeigy DeKalb, Ill. 60115 280 Park Ave. 444 Saw Mill River Rd. Diagnon Corp. New York, N.Y. 10017 Ardsley, N.Y. 10502 225 Main St. Brain Research Clonal Research Westport, Corm. 06880 46 East 91st St. 1598 Monrovia Ave. Diagnostic Technology, Inc. New York, N.Y. 10028 Newport Beach, Calif. 92630 240 Vanderbilt Motor Parkway Bristol-Myers Co. Codon Hauppauge, N.Y. 11788 Industrial Division 430 Valley Dr. P.O. BOX 657 Brisbane, Calif. 94005 Syracuse, N.Y. 13201 544 . Commercial Biotechnology: An International Analysis Diamond Laboratories Enzyme Technology Corp. Genex Corp. 2538 S.E. 43rd St. 783 U.S. 250 East, Route 2 6110 Executive Blvd. Des Moines, Iowa 50316 Ashland, Ohio 44805 Rockville, Md. 20852 Diamond Shamrock Corp. Ethyl Corp. Gentronix Laboratories, Inc. T. R. Evans Research Center P.O. Box 341 15825 Shady Grove Rd. Rockville, Md. 20850 P.O. BOX 348 Baton Rouge, La. 70821 Gainesville, Ohio 44077 Exxon Research & Engineering Co. Genzyme DNA Plant Technology 180 Park Ave. 1 Bishop St. 2611 Branch Pike Florham Park, N.J. 07932 Norwalk, Corm. 06851 Cinnaminson, N.J. 08077 Fermentec Corp. W. R. Grace & Co. DNAX Corp. 301 Saratoga Ave. Research Division 1454 Page hfill Rd. Los Gates, Calif. 95030 7379 Route 32 Palo Aho, Calif. 94304 FMC Corp. Columbia, Md. 21044 Dow Chemical Co. 2000 Market St. Hana Biologics, Inc. 2030 Dow Center Philadelphia, Pa. 19103 626 Bancroft Way Midland, Mich. 48640 Frito-Lay, Inc. Berkeley, Calif. 94710 Ean-tech, Inc. Frito-Lay Tower Hem Research 699-A Cerramonte Blvd. Exchange Park 12220 Wilkins Ave. Dale City, Cdif. 94015 P.O. Box 35034 Rockville, Md. 20852 Dallas, Tex. 75235 Eastman Kodak Co. Hoffmann-La Roche, Inc. 343 State St. Fungal Genetics, Inc. 34o Kingsland St. Rochester, N.Y. 14650 14721 Cottonwood P1. Nutley, N.J. 07110 Bothell, Wash. 98011 Ecogen, Inc. Hybridoma Sciences, Inc. c/o Johnston Associates, Inc. Genencor 4761 Hugh HowelI Rd., Suite D 1101 State Rd., Bldg. O Baron Steuben P1. Tucker, Ga. 30084 Princeton, N.J. 08540 Corning, N.Y. 14870 Hybritech, Inc. E. 1. du Pent de Nemours & Co. Genentech, Inc. 11085 Torreyana Rd. Central Research and Development 460 Point San Bruno Blvd. San Diego, Calif. 92121 Department South San Francisco, Calif. 94080 Hytech Biomedical, Inc. 1007 Market St. General Electric Co. 1440 Fourth St. Wilmington, Del. 19898 Research and Development Berkeley, Calif. 94710 Electro Nucleonics Laboratories, Inc Laboratories IBM Corp. 12050 Tech Rd. One River Rd. Thomas J. Watson Research Center Silver Spring, Md. 20904 Schenectady, N.Y. 12345 Yorktown Heights, N.Y. 10598 Eli Lilly & Co. General Foods Corp. IGI Biotechnology, Inc. Lilly Research Laboratories 555 South Broadway 9110 Red Branch Rd. 307 East MKarty St. Tarrytown, N.Y. 10591 Columbia, Md. 21045 Indianapolis, Ind. 46285 General Genetics Immulok, Inc. EnBio, Inc. 15400 West 44th Ave. 1019 Mark Ave. Union Ave. #408A Golden, Colo. 80403 Carpinteria, Calif. 93013 Fairfield, Calif. 94533 General Molecular Applications Immunetech, Inc. Endorphin, Inc. 1834 Elmwood Ave. 8950 Villa La Jolla Dr., Suite 2132 1000 Seneca St. Columbus, ohio 43212 La Jolla, Calif. 92037 Seattle, Wash. 98111 Genetic Diagnostics Corp. Immunex Corp. Engenics, Inc. 160 Community Dr. 51 University Bldg., Suite 600 2 Palo Alto Sq., Suite 500 Great Neck, N.Y. 11021 Seattle, Wash. 98101 Palo Alto, Calif. 94304 Genetic Replication Technologies, Inc Immuno Modulators Laboratories, Inc. Enzo Biochem, Inc. 1533 Monrovia Ave. 10511 Corporate Dr. 325 Hudson St.
Load more

Recommended publications
  • Polio Vaccine Safety Paul Meier's Role in the Discovery And
    www.barkerstats.com Polio Vaccine the cutter incident October 1, 2020 Downloaded from www.barkerstats.com/PDFs/Meier/Meier-Cutter-Incident-History.pdf Polio Vaccine Safety Paul Meier’s Role in the Discovery and Evaluation of The Cutter Incident Professor Chris Barker, Ph.D. Adjunct Associate Professor of Biostatistics, UIC SPH. www.barkerstats.com Page 1 of 11 www.barkerstats.com Polio Vaccine the cutter incident October 1, 2020 Contents Background .................................................................................................................................................................................................................... 3 Brief Polio Vaccine Overview ......................................................................................................................................................................................... 3 Polio Vaccine Manufacturing Data Suppression ............................................................................................................................................................ 4 Biological Disaster? How Serious was the vaccine manufacturing problem? ............................................................................................................... 5 Near Elimination of Vaccine development by lawsuits ................................................................................................................................................. 6 Meier’s evaluation of the safety recommendations following The Cutter Incident ....................................................................................................
    [Show full text]
  • Our Global Initiative
    2021 OUR GLOBAL INITIATIVE AN ASSESSMENT OF COVID-19 & THE FAILED GLOBAL HEALTH POLICIES OF THE WHO OUR GLOBAL INITIATIVE In early 2020, Australia, and indeed the world, collapsed into a lockdown prompted by the World Health Organisation in its designation of Covid 19 as a pandemic. What began as “2 weeks to flatten the curve” quickly morphed into a year of intermittent lockdowns, a loss of freedoms and liberties, the decimations of SME’s, irrational restrictions, unadulterated government surveillance, an endless state of emergencies, the rise of the police state a totalitarian grand stride towards medical fascism and a technocratic dictatorship as well as the end of civil society as we know it. What happened? How did we get here? Where are we going? What does this world of the “New Normal” hold for not only Australia, but the human civilisation? How do we navigate this reality and not only survive but thrive? The Global Health Organisation, in collaboration with the Australian Patriots Alliance, the World Solutions Foundation, the QuantumPrism Foundation, Ikighais Pty Ltd and other concerned institutions (the Initiative) have commissioned this report in effort to gain an insight into what is going on; the why, they how and the WHO! Further, the report will offer solutions to current concerns, as well as ways for interested parties to position themselves to thrive and win in the new society bound to emerge from the ashes of this dying world. 2 TIPS TO HELP READ THIS REPORT This report contains a lot of information and we appreciate SUMMARY POINTS that time is scarce.
    [Show full text]
  • Chronological Introduction of Types of Vaccine Products That Are Still Licensed in the United States
    Appendix 2.3 CHRONOLOGICAL INTRODUCTION OF TYPES OF VACCINE PRODUCTS THAT ARE STILL LICENSED IN THE UNITED STATES The year of introduction of each of 49 of the 51 shown in table 2.3B, American pharmaceutical com- types of vaccine prducts currently licensed in the panies were issued 37 (89 percent) of the original United States, alolng with the manufacturing estab- licenses for these 42 products. New or improved lishment with the oldest license still in effect for each types of products that are currently licensed have product, is shown in table 2.3 A.] For 42 (86 percent) been introduced at a fairly consistent rate of three to of these 49 products, the establishment that received seven products per each 5-year interval since 1940.2 the original product license still holds this license. As Ten of the currently licensed products were licensed before 1940. Table 2.3A—Chronological Introduction of Types of Vaccine Products Still Licensed in the United States Year Type of vaccine product Establishment with oldest product license still in effecta 1903 Dlphtherla antitoxin Massachusetts Public Health Biologic Laboratories (191 7) 1907 Tetanus antitoxin Parke. Davis and Company (191 5) 1914 Pertussis vaccine Lederle Laboratories Typhoid vaccine Massachusetts Public Health Biologic Laboratories (191 7) Rabies vaccine . Eli Lilly and Company* 1917 Cholera vaccine Eli Lilly and Company* 1926 Diphtheria toxoid Parke, Davis and Company (1927) 1933 Staphylococcus toxoid Lederle Laboratories* Tetanus toxoid Merck Sharp and Dohme 1941 Typhus vaccine Eli Lilly and Company 1942 Plague vaccine .., . Cutter Laboratories* Rocky Mountain Spotted Fever vaccine. Lederle Laboratories* 1945 InfIuenza virus vaccine Lederle Laboratories Merck Sharp and Dohme Parke, Davis and Company * 1946 Parke, Davis and Company ● 1947 Parke, Davis and Company (1949) 1948 Parke, Davis and Company (1952) Parke.
    [Show full text]
  • The Academic Model for the Prevention and Treatment of HIV
    C A S E S I N G L O B A L H E A L T H D ELIVERY GHD-045 JULY 2021 Building the Supply Chain for COVID-19 Vaccines Mid-April 2020 saw a rapid escalation of the COVID-19 pandemic. In the four months after December 2019, when the novel coronavirus that causes COVID-19 was first detected in Wuhan, China, the virus had infected several million people globally, with more than a hundred thousand confirmed deaths (see Exhibit 1 for daily confirmed deaths by country). China and Italy experienced major outbreaks early and saw hospitals flooded with COVID-19 patients, causing major shortages of vital intensive-care materials. To forestall the overburdening of health care resources, more than a dozen major countries imposed strict lockdowns to slow the spread of the disease, or “flatten the curve” (see Exhibit 2 for a map of government responses). Government lockdowns disrupted supply and demand in vital industries including retail, tourism, manufacturing, and services, crippling the global economy. As the massive scale of the crisis became apparent, financial markets began to collapse during February, leading some experts to warn of a potential next Great Depression and governments to announce unprecedented rescue packages to contain the destructive economic impact of the crisis. As governments navigated trade-offs between economic and public health outcomes, a global race had begun for the rapid discovery, production, and distribution of a safe and effective vaccine. The organization of supply chains to manufacture, distribute, and administer a vaccine to a sufficient portion of the 7.6 billion world population to contain the disease, a concept termed “herd immunity,” posed significant challenges.
    [Show full text]
  • Robert J. Desalvo Papers Business Combinations in the Cosmetic and Pharmaceutical Industries 1944
    Robert J. DeSalvo Papers Business Combinations in the Cosmetic and Pharmaceutical Industries 1944 - 1990 Collection #107 Abstract Robert J. DeSalvo’s research focused on business combinations (acquisitions, mergers, and joint ventures in the cosmetic and pharmaceutical industries. This topic was the basis for his master’s thesis in pharmacy administration at the University of Pittsburgh and continued as a life-long interest. This collection consists of two series of notebooks that Dr. DeSalvo developed to record relevant business combinations. The first series records acquisitions, proposed acquisitions, mergers, and joint ventures for the period of 1944 –1990 in an alphabetical arrangement. The information on these entries is cumulative so that the history of an organization is collected in one place. The second series of notebooks is arranged in chronological blocks. The information is arranged alphabetically by the name of the acquirer. The name of the acquired (merged), type of combination (acquisition, proposed acquisition, joint venture) and the date is also provided. The information is cross-referenced between the two series so that the researcher can approach the information by the name of the parent company or chronologically. Dr. DeSalvo used this resource for many of his publications as well as his master’s thesis. A copy of these publications and his thesis make up the remainder of the collection. Donor Gift of Barbara DeSalvo, 2000 Biography Robert James DeSalvo was born on July 20, 1933 in Toledo, OH. He died on January 23, 1993 in Cincinnati, OH. DeSalvo graduated from high school in Toledo and attended pharmacy school at the University of Toledo where he received his B.S.
    [Show full text]
  • [1] Vaccination Update Table of Contents: 1
    EYE ON THE MARKET • MICHAEL CEMBALEST • J.P. MORGAN Last updated 9/23/2021 [1] Vaccination update Table of Contents: 1. US vaccination overview ................................................................................................................................2 2. Vaccination vs infection, mortality, hospitalization and 2020 Trump voting share ............................................3 3. “A pandemic of the unvaccinated” .................................................................................................................4 4. Population shares, vaccine efficacy and the amalgamation paradox ................................................................5 5. Vaccine efficacy tracker ..................................................................................................................................6 6. Vaccination vs previous COVID infection (acquired vs natural immunity) .........................................................7 7. Vaccine risk-benefit data ................................................................................................................................8 8. Variant prevalence by country ........................................................................................................................9 9. Delta variant facts and figures ........................................................................................................................9 10. Vaccine update by country and US state ......................................................................................................
    [Show full text]
  • Process Paper and Bibliography
    From Miracle To Mishap: The Cutter Incident and its Impact on Modern Vaccine Safety Standards Melinda Chen Senior Division Individual Documentary Process Paper: 488 Words This year, I wanted to explore a topic that was both outside of my comfort zone and relevant to modern times. The topic of vaccines first caught my attention after I heard about the resurgence of measles and other preventable diseases in America. From there, I encountered many sources which vaguely referenced a past safety issue with the polio vaccine. I decided to dig deeper, and discovered that this ‘issue’ was the Cutter Incident, a catastrophe in which over 120,000 people received polio vaccines containing live virus. I soon realized that the Cutter Incident was both a perfect fit for this year’s theme of Triumph and Tragedy, as well as story waiting to be told. I started my research by looking at secondary sources, especially books, to get a general idea of the topic. Next, I turned to primary documents and accounts, including those found in the Alan Mason Chesney Medical Archives, the U.S. National Library of Medicine, and the National Archives for more specific information including statistics and correspondences between government officials. I also wanted to hear from people who could provide different perspectives regarding the incident, which led to me reaching out to Dr. Peter Salk, Dr. Paul Offit, and Anne Gottsdanker for interviews. Dr. Salk and Ms. Gottsdanker were especially helpful since, as the son of Jonas Salk and a victim of the Cutter Incident respectively, they were able to give perspectives that I could not find in any other source.
    [Show full text]
  • A Successful Vaccine That Missed Its Target
    BOOK REVIEW A successful vaccine that missed stringent than those established by Salk and the National Foundation for Infantile Paralysis, leaving the door open to flexible interpretations by indi- its target vidual manufacturers. The black sheep proved to be Cutter Laboratories, but other manufacturers also had problems in avoiding live virus in some The Cutter Incident: How America’s of their vaccine lots. At the time of the incident, regulatory agencies in First Polio Vaccine Led to the charge of vaccine safety were still at an embryonic stage and certainly not Growing Vaccine Crisis in a position to ascertain the absence of live viruses in the inactivated polio vaccine. The importance of lot-to-lot consistency was not yet fully realized, By Paul A Offit and communication was limited between the different players. Yale University Press, 2005 In today’s context, it is not surprising that what could go wrong did go wrong. Offit clearly explains the technical reasons accounting for the 256 pp., hardcover, $27.50 persistence of live virulent polio virus in the Cutter vaccine. He notes that ISBN 0300108648 several of the vaccine lots produced by Cutter were found by the company Reviewed by Paul-Henri Lambert to be contaminated with live virus and were discarded. This obviously http://www.nature.com/naturemedicine reflected serious lot-to-lot discrepancies and indicated major problems in the production line. It is still puzzling why this did not raise more aware- In April of 1955, fearing the polio epidemic sweeping the US, Josephine ness of a potential risk. Gottsdanker took her five-year-old daughter Anne to the pediatrician to For those who are not familiar with the heavy regulatory environment receive Jonas Salk’s new polio vaccine.
    [Show full text]
  • Tecncal Report on Poliomyelitis Vaccine
    Tecncal Report on Poliomyelitis Vaccine N .June 10. 1955, the Puiblic Health Service tories whiclh might wish to manufacture and sent a Teclhniical Report on the Salk store vaccine intended for commercial use pend- l'oliomiivelitis Vaccine to the Secretary of ing decision to license the product. Whlen the Healtlh, Education, anid Welfare. Publislhed success of the field trial was reported April 12, below are the sumnmary. the report on epi- 1955. official minimum requirements were is- deemiological experience and new developments sued. Six manufacturers, each of which had in biologrics, and an expan(ledl calendar of eveents. produced vaccine under the provisional require- Copies of the r-eport were inade available to all ments, were granted licenses. State an(l local lhealtlh departments. Since only Records and samples of vaccine lots had been a limite(ld unuber of copiesare available throllugh submitted to the Public Healtlh Service Labora- the Puiblic Ilealtlh Service, it is recommenided tory of Biologics Control prior to April 12, and, that initerestedl lhealth departtment employees witlhin the next few davs, tlhose which were con- obtain a copy in their own agency. sidered acceptable, were released. Most bio- logical products for commercial distribution are released on the basis of an examination of Summary the detailed record of events in maniufacture The report presenits the teelhnical problems ani(l testingc, (known as a protocol), with or involve(d in the product ion, testinl, anid safety witlhout futrther testing by the Laboratory of of Salk polioiimvelitis vaccine. It also describes Biologics Cointrol. Release of most of the lots the responsibilities of tlhe lPublic Health Serv- of polionmyvelitis vaccine was based on review ice in control of the mianuflachitue of the vaccine of the manufacturing, protocols.
    [Show full text]
  • Recalibrating Vaccination Laws
    RECALIBRATING VACCINATION LAWS EFTHIMIOS PARASIDIS INTRODUCTION ............................................................................................. 2154 I. PLACING THE VACCINE ACT IN HISTORICAL CONTEXT ..................... 2166 A. Manufacturer’s Liability for Vaccine-Related Injuries ............. 2167 1. The Cutter Incident and Vaccine-Induced Polio ................. 2167 2. Cancer and SV40 Contaminated Polio Vaccines ................. 2172 3. Products Liability Claims for Vaccine-Related Injuries ...... 2178 4. Vaccine-Related Injuries and Market Share Liability ......... 2186 B. The 1976 Swine Flu Vaccine: Industry Demands Government Indemnification for Vaccine-Related Injuries ........................... 2192 C. 1980s Public Health Politics: Portraying the FDA as a Bureaucratic Hindrance to Health and Safety .......................... 2200 II. THE VACCINE ACT FRAMEWORK ...................................................... 2208 A. National Vaccine Program: Goals, Funding, and Administration ........................................................................... 2209 B. The National Vaccine Injury Compensation Program .............. 2211 C. The Vaccine Act’s Limits on Tort Claims Against Vaccine Manufacturers ........................................................................... 2219 III. MODERNIZING THE VACCINE ACT ..................................................... 2221 A. Adjusting the Requirements for Adverse Event Reporting and Post-Market Analysis of Vaccine Safety and Efficacy ............... 2222 B. Predicating
    [Show full text]
  • Polio and Eli Lilly and Company
    Polio and Eli Lilly and Company While polio has a history that some say dates back to ancient times, it was not until 1789 that British physician Michael Underwood provided the first clinical description of the disease.1 The first outbreaks of polio in the United States were in 1894, with a major epidemic occurring in the summer of 1916 when thousands of children in New York, New Jersey, Pennsylvania, and Connecticut experienced unusual and frightening symptoms. 2 First, they came down with an apparent cold accompanied by a headache and chills. Soon, without warning, they might wake up partially paralyzed. Some victims even became unable to swallow or breathe due to paralyzed muscles. By mid-August that year, 9,000 children had exhibited these symptoms.3 No one knew what the disease was or how it was contracted, but they did know that children were disproportionately affected, which led to increased fear and panic. Autopsies revealed an inflammation of the anterior spinal cord. Thus the disease got its name – poliomyelitis.4 Various measures were taken to try to control the disease and to stop its spread. According to one source, New York City scrubbed the streets with four million gallons of water a day and killed 72,000 stray cats in an effort to destroy polio germs.5 In her book Patenting the Sun: Polio and the Salk Vaccine, Jane S. Smith noted: Nonresident bathing was banned at the Hudson Park Beach. Sunday schools were closed, and children under sixteen were forbidden to attend the local vaudeville theatres. Travelers were stopped at the city limits and issued transit passes good for one-half hour.
    [Show full text]
  • Commercial Biotechnology: an International Analysis
    Index . Index Abbott Laboratories, 149, 196 generic applied research, 312 Abello Co. (F. R.G.), 130 international comparisons, 317 acquired immunedeficiency syndrome (AIDS), 125, 132 issues and options, 325 Advanced Genetic Sciences, Inc., 82 National Institutes of Health, 310, 323 Agent Orange, 222 National Science Foundation, 310 Agricultural Genetics (U.K.), 71, 82, 320, 425 USDA, 311, 323 Ajinomoto Co., 83, 131, 196, 197, 505 Baxter Travenol Laboratories, 134, 196 Allied Corp., 82 Baxter, William, Assistant Attorney General, 436 American Association for the Advancement of Science, Bayer Co., 83 309 Beckman Instruments, 87, 88 American Association of Universities, 421 Becton Dickinson Co., 145 American Cancer Society, 123 Beecham Co. (U.K.), 75 American Commercial Co., 87 Bell Laboratories, 308, 532 American Cyanamid, 80, 81, 167 Berkey Photo, Inc. v. Eastman Kodak Co., 440 American Hospital Supply, 196 Bethesda Research Laboratories, 84, 199 American Society for Engineering Education, 341 bioelectronics, 7, 253-256 Amgen Co., 80, 130, 149, 167 biochips, 254 Amicon Co., 54, 88 biosensors, 253 analysis, framework for, 263-266 future research, 256 competitiveness in biotechnology, factors influencing, bioengineering, novel techniques, 3, 4, 25 263 Biogen Co., 99, 101, 122, 133, 134 firms commercializing biotechnology, 265 Bio Logicals, 85, 90 Anheuser Busch, 102, 247 Biopol@, 211 animal agriculture industry, 6, 79-81, 162-171 bioprocessing separation and purification animal nutrition and growth promotion, 167 instrumentation, 88 commercial
    [Show full text]